Cytosorbents Corporation (NASDAQ: CTSO)
$0.8902
+0.0518 ( +2.32% ) 77.9K
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
Market Data
Open
$0.8902
Previous close
$0.8384
Volume
77.9K
Market cap
$47.81M
Day range
$0.8360 - $0.9020
52 week range
$0.7000 - $1.8200
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Apr 04, 2024 |
4 | Insider transactions | 1 | Apr 04, 2024 |
4 | Insider transactions | 1 | Apr 04, 2024 |
8-k | 8K-related | 15 | Apr 03, 2024 |
4 | Insider transactions | 1 | Apr 02, 2024 |
4 | Insider transactions | 1 | Apr 02, 2024 |
4 | Insider transactions | 1 | Apr 02, 2024 |
4 | Insider transactions | 1 | Apr 02, 2024 |
8-k | 8K-related | 16 | Mar 15, 2024 |
10-k | Annual reports | 90 | Mar 15, 2024 |